Japan Selects NEC and Waseda Consortium for Quantum Computing Cancer Immunotherapy Programme

Japan's New Energy and Industrial Technology Development Organization has selected a consortium of NEC Corporation, Taiho Pharmaceutical, the Japanese Foundation for Cancer Research, AIST and Waseda University for a demonstration programme applying quantum computing to cancer immunotherapy. The project, running from September 2026 through March 2029, will develop a computational platform for designing next-generation cancer treatments.

The programme will use quantum computing and AI to design and optimise neoantigen candidate sequences — personalised peptides that can train a patient's immune system to recognise and attack their specific tumour. The focus on CD4-positive T cell responses through MHC class II represents an approach distinct from most current immunotherapy strategies, which primarily target CD8 T cells.

NEC brings its quantum computing hardware and software expertise, while Taiho Pharmaceutical provides drug development capabilities and the Japanese Foundation for Cancer Research offers clinical validation pathways. The involvement of AIST, Japan's national research institute, adds computational infrastructure and materials science support.

The project represents one of the most concrete applications of quantum computing to drug discovery currently underway. While quantum advantage in pharmaceutical applications remains largely theoretical, Japan's willingness to fund a multi-year demonstration programme signals growing confidence that quantum approaches could accelerate specific computational bottlenecks in drug design. The programme is part of Japan's broader strategy to maintain competitiveness in both quantum technology and pharmaceutical innovation.